Table 2.

Baseline characteristics of included trials in the meta-analysis

Study	Group	Age	Gender	Intervention	Time of intervention	Bowel preparation	Colonoscopy staff	Sedation
			(M/F)
Byun et al[20]	Hyoscine butylbromide	Not mentioned	103 (total number)	20 mg, iv	At the time of colonoscopic withdrawal	Not mentioned	Not mentioned	Not mentioned
	Placebo		102 (total number)	1 mL NS, iv
Lee et al[21]	Hyoscine butylbromide	59.4 ± 8.5	27/31	20 mg, iv	When the scope reached the cecum	Polyethylene glycol solution	A single experienced endoscopist	Midazolam, 3-5 mg, iv
	Placebo	58.4 ± 7.9	23/35	1 mL NS, iv
Corte et al[10]	Hyoscine butylbromide	60.6 ± 11.2	162/141	20 mg, iv	After the cecum was reached	PrepKit C; picoPrep; moviPrep; glycoPrep	8 endoscopists, 14 fellows	Midazolam, fentanyl with or without propofol, iv
	Placebo	61.4 ± 10.4	157/141	1 mL NS, iv
de Brouwer et al[15]	Hyoscine butylbromide	61.5	156/184	20 mg, iv	When the cecum was reached and the withdrawal of the colonoscope was started	Polyethylene glycol solution	5 gastroenterologists and 3 nurse endoscopists	Not mentioned
	Placebo	61.4	176/158	1 mL NS, iv
Rondonotti et al[16]	Hyoscine butylbromide	57.3 ± 11.5	90/112	20 mg, iv	At cecal intubation	Senna-based preparation	Six board-certified gastroenterologists	Midazolam and pethidine, iv
	Placebo	57.3 ± 13.5	87/113	1 mL NS, iv